drugset / Trial / NCT00932737

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

NCT00932737

Phase 2 Completed 197 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment of intensity of abdominal pain associated with cramping (APC) in the treatment of two episodes.

Timeline

Start
2009-06-09
Primary completion
2010-02-08
Completion
2010-02-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hyoscine butylbromide Unknown 20 mg

Indications

No indication recorded.